Patents by Inventor Jorge ESQUIVIAS PROVENCIO

Jorge ESQUIVIAS PROVENCIO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrazole compounds and their use in the treatment of tuberculosis
    Patent number: 11072591
    Abstract: The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by Mycobacterium, such as tuberculosis.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: July 27, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Carlos Alemparte-Gallardo, Lourdes Encinas, Jorge Esquivias Provencio
  • NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS
    Publication number: 20200231555
    Abstract: The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by Mycobacterium, such as tuberculosis.
    Type: Application
    Filed: August 16, 2018
    Publication date: July 23, 2020
    Inventors: Carlos ALEMPARTE-GALLARDO, Lourdes ENCINAS, Jorge ESQUIVIAS PROVENCIO
  • Antituberculosis agent
    Patent number: 10624893
    Abstract: The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 21, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Lluis Ballell Pages, David Barros Aguirre, Robert H. Bates, Julia Castro Pichel, Jorge Esquivias Provencio, Kevin Pethe
  • ANTITUBERCULOSIS AGENT
    Publication number: 20190091224
    Abstract: The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 20, 2017
    Publication date: March 28, 2019
    Inventors: Lluis BALLELL PAGES, David BARROS AGUIRRE, Robert H. BATES, Julia CASTRO PICHEL, Jorge ESQUIVIAS PROVENCIO, Kevin PETHE